Drug intelligence / Profile preview

Sensicutan

Development stage
Unknown
Lead developer
Harras Pharma Curarina
Modality
Small Molecules
Administration
Topical
01

Overview

Sensicutan is a topical cream developed and marketed by Harras Pharma Curarina, primarily indicated for the treatment of inflammatory and pruritic skin conditions such as eczema, neurodermitis, and itching. It is a cortisone-free formulation that utilizes a combination of two active ingredients: Heparin Sodium (20,000 I.E. per 100g) and Levomenol (alpha-bisabolol, 0.3g per 100g). Heparin provides anti-inflammatory and anti-exudative effects, while Levomenol, a natural constituent derived from chamomile, offers additional anti-inflammatory and soothing properties. Although some provided documentation describes the product as a comfrey-based formulation for pain and wound healing, the established pharmaceutical product in Germany is defined by the heparin-bisabolol combination. It is available in 30g and 80g tubes and is classified under the ATC code D11AX50.

Brand names
Sensicutan
Other names
comfrey-based cream
02

Targets

COXATIII (Antithrombin III)

Beyond the preview

Go deeper on Sensicutan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sensicutan.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call